Genelux Corporation reported a net loss of $32.1 million for 2025 and a quarterly loss of $7.95 million for Q4 2025, a decline from the $29.9 million loss recorded in 2024. The company’s cash, cash equivalents, marketable securities and restricted cash totaled $33.1 million as of December 31 2025, after raising $18.5 million in net proceeds from a public offering on January 8 2026. The pro‑forma balance is projected to fund operations through the first quarter of 2027, giving management a clear runway to pursue key clinical milestones.
Continue reading for full analysis...